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Abstract 
Introduction: Antimicrobial resistant bacterial infections are widespread globally and increases in antimicrobial resistance presents a major 
threat to public health. Pseudomonas aeruginosa is an opportunistic healthcare-associated pathogen with high rates of morbidity and mortality 
and an extensive range of resistance mechanisms. This study describes the antibiotic susceptibility profiles of P. aeruginosa isolates from 
patients with bacteraemia submitted by sentinel laboratories in South Africa from 2014 to 2015.  
Methodology: Organism identification and antimicrobial susceptibility testing were done using automated systems. Molecular methods were 
used to detect common resistance genes and mechanisms.  
Results: Overall the susceptibility was high for all antibiotics tested with a decrease over the two-year period. There was no change in the 
MIC50 and MIC90 breakpoints for all antibiotics from 2014 to 2015. The MIC50 was within the susceptible breakpoint range for most antibiotics 
and the MIC90 was within the susceptible breakpoint range for colistin only. Phenotypically carbapenem non-susceptible isolates harboured the 
following plasmid-mediated genes: blaVIM (n = 81, 12%) and blaGES (n = 6, 0.9%); blaNDM (n = 4, 0.6%) and blaOXA-48 and variants (n = 3, 
0.45%). Porin deletions were observed in one meropenem non-susceptible isolate only, and multi-drug resistance efflux pumps were expressed 
in the majority of the non-susceptible isolates investigated. BlaVEB-1, blaIMP and blaKPC were not detected.  
Conclusion: The prevalence of resistance to commonly used antibacterial agents was low for P. aeruginosa isolates and similarly, tested 
resistance mechanisms were detected in a relatively small proportion of isolates. Findings in this study represent baseline information for 
understanding antimicrobial susceptibility patterns in P. aeruginosa isolates from blood. Our surveillance report may assist in contributing to 
hospital treatment guidelines.  
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Introduction 
Pseudomonas aeruginosa is an opportunistic 
nosocomial pathogen with high rates of morbidity and 
mortality in infected patients [1]. Treatment is 
challenging due to the presence of intrinsic 
antimicrobial resistance genes and the organism’s 
ability to acquire genes encoding multiple resistance 
mechanisms [2,3]. These mechanisms of resistance 
often exist simultaneously and confer combined 
resistance to the bacterial isolate [4]. Intrinsic resistance 
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may be due to the production of an inducible AmpC β-
lactamase; low permeability of the cell wall due to a 
porin loss; and upregulation of multi-drug resistant 
efflux pump systems. Acquired resistance is due to the 
acquisition of additional resistance genes on mobile 
genetic elements such as plasmids, transposons and 
bacteriophages from other organisms and due to 
mutations in chromosomal genes that upregulate 
resistance genes [5-7]. P. aeruginosa is naturally 
susceptible to carboxypenicillins, ureidopenicillins 
(e.g. piperacillin); some third- and fourth-generation 
cephalosporins (e.g. ceftazidime and cefepime), 
monobactams (e.g. aztreonam), carbapenems (e.g. 
imipenem, meropenem, doripenem), aminoglycosides 
and fluoroquinolones (e.g. ciprofloxacin). Resistance to 
penicillins and cephalosporins may be due to 
hyperproduction (or derepression) of Amp-C 
cephalosporinases which are chromosomally encoded 
[7-9]. Protein channels (porins) allow the uptake of 
nutrients and other important substances into the cell 
including antimicrobial agents [10]. Mutational 
impermeability due to the loss of OprD, a porin that 
forms narrow transmembrane channels in the outer 
membrane, results in resistance to carbapenems 
particularly imipenem and reduced susceptibility to 
meropenem. Mutations can result in porin loss, a 
modification in the size of the porin channel or a 
reduction in expression of the porin. Resistance-
nodulation-division (RND) bacterial efflux pumps are a 
family of transporters that play an important role in 
virulence, stress responses and clinical resistance. 
These pumps are regulated by regulators (repressors or 
activators), modulators and two-component regulatory 
systems in which mutations can result in antimicrobial 
resistance [11]. The upregulation of efflux pumps 
confers resistance to a host of antimicrobial agents: 
MexAB-OprM upregulation confers resistance to the 
penicillins, fluoroquinolones, cephalosporins and to a 
lesser degree, meropenem; MexCD-OprJ and MexEF-
OprN upregulation causes resistance to 
fluoroquinolones and some beta–lactams; while 
MexXY-OprM upregulation leads to aminoglycoside 
resistance [7,9,12,13]. Acquired resistance to 
antibiotics in the beta-lactam group including the 
penicillins, cephalosporins, monobactams and 
carbapenems is due to the acquisition of genes encoding 
antimicrobial hydrolysing enzymes such as the 
Pseudomonas specific enzymes (PSE) PSE-1 and PSE-
4; the extended-spectrum beta-lactamases (ESBL) 
TEM, SHV, VEB, GES, PER and BEL types; the 
oxacillinases (OXA) and the metallo-beta-lactamases 
(MBL) NDM, IMP and VIM [7,9]. Acquired resistance 
to colistin may be due to the presence of the plasmid-
mediated mcr-1 gene [14].  
In South Africa there have been reports of multi-
drug resistant P. aeruginosa infections causing 
outbreaks in various hospitals [15-17] justifying the 
need for national surveillance of this pathogen in order 
to monitor antimicrobial resistance trends. A national 
surveillance programme as outlined and advocated by 
the World Health Organisation (WHO) will assist in 
creating awareness among clinicians and the general 
public on the appropriate use of antibiotics [18]. The 
Antimicrobial Resistance Laboratory (AMRL) at the 
Centre for Healthcare-associated infections, 
Antimicrobial Resistance and Mycoses (CHARM) 
utilising the GERMS-SA platform has therefore 
established a laboratory-based antimicrobial resistance 
surveillance system for nosocomial pathogens. In this 
study the antibiotic susceptibility profiles of P. 
aeruginosa isolates from patients with bacteraemia and 
positive blood cultures were determined. Isolates were 
obtained from 12 sentinel sites from four provinces in 
South Africa. Various resistant phenotypes and 
genotypes of P. aeruginosa from 2014 to 2015 were 
characterised to determine antimicrobial susceptibility 
profiles and common resistance mechanisms among 
pathogenic strains. 
 
Methodology 
Patient selection 
P. aeruginosa blood culture isolates were submitted 
to the Centre for Healthcare-associated infections, 
Antimicrobial Resistance and Mycoses (CHARM) at 
the National Institute for Communicable Diseases 
(NICD) from 12 public healthcare sector academic 
centers in four provinces in South Africa: Gauteng, 
KwaZulu-Natal, Free State and the Western Cape. 
Demographic information was obtained from the 
laboratory request form. A three-week exclusion period 
was applied to avoid duplicate isolates of the same 
organism from the same patient. Audit cases were 
defined as those cases that were identified according to 
the public healthcare sector Corporate Data Warehouse 
(CDW) but not received for processing in the 
laboratory. The CDW houses records of patient details 
and laboratory results. 
 
Phenotypic methods 
When isolates were received in the AMRL, 
organism identification was confirmed using automated 
systems (VITEK II (bioMèrieux, Marcy-l'Etoile, 
France) and/or the Microflex MALDI-ToF (Bruker 
Daltonik, GmbH). To resolve a conflict in the organism 
Singh-Moodley et al. – Antimicrobial resistance in P. aeruginosa isolates    J Infect Dev Ctries 2018; 12(8):616-624. 
618 
identification between the sending and reference 
laboratories, 16s rRNA sequencing was performed 
(Inqaba Biotec, Pretoria, South Africa). Antimicrobial 
susceptibility testing (AST) was performed using the 
MicroScan Walkaway system (Siemens, Sacramento, 
CA, USA). Susceptibility results were interpreted 
according to the Clinical and Laboratory Standards 
Institute (CLSI) guidelines [19]. The Sensititre 
instrument (Trek Diagnostic Systems, Cleveland, Ohio, 
USA) was used for colistin susceptibility and was 
interpreted according to the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST) 
guidelines [20]. 
 
Genotypic methods 
Molecular resistance mechanisms were determined 
for different isolates based on the phenotypic 
susceptibility results. In brief, for those isolates 
displaying:  
 Carbapenem resistance were selected for the 
detection of carbapenemases blaNDM, blaIMP, blaVIM; 
blaOXA-48 and its variants, blaKPC and blaGES as well 
as porin (OprD) deletion.  
 Resistance to any of the beta-lactams were selected 
for the detection of the ESBL, blaVEB-1.  
 Resistance to the fluoroquinolones and/or 
aminoglycosides and/or β-lactams (pipercillin, 
cefepime, ceftazidime) were selected for testing for 
the expression of the efflux pumps MexAB-OprM, 
MexXY-OprM, MexCD-OprJ and MexEF-OprN.  
 
the DNA was extracted using a crude boiling 
method. Half a 1 µL loop-full of subculture was 
resuspended in Tris-EDTA (ethylenediamine tetra-
acetic acid) buffer and heated at 95oC for 25 minutes. 
The bacterial cells were lysed and the supernatant 
containing the DNA was harvested and stored at -70oC 
for further screening.  
BlaNDM, blaIMP, blaVIM, blaOXA-48 and its variants, 
blaKPC and blaGES, were screened for using a multiplex 
real-time polymerase chain reaction (PCR) 
(LightCycler 480 II, Roche Applied Science, Penzberg, 
Germany; LightCycler 480 Probes Master kit, Roche 
Diagnostics, Indianapolis, USA) and the individual 
LightMix Modular carbapenemase kits (Roche 
Diagnostics, Indianapolis, USA). The G-Storm 
(Somerton Biotechnology Centre, Somerton, UK) 
thermal cycler was used for the conventional singleplex 
PCRs of blaVEB-1 and OprD porin deletions using the 
Qiagen Multiplex PCR kit (Qiagen, Nordrhein-
Westfalen, Germany) with previously published 
primers [12,21]. Because the OprD region is a 
hypervariable region and variants may be present, two 
PCRs may have been required i.e. in cases of the first 
PCR not amplifying the target, an alternate PCR for this 
gene was performed according to a previous publication 
[12]. The presence of this gene following both PCRs 
indicates the absence of a porin deletion i.e. there was 
no reduction of the transmembrane channels (porins). 
The absence of this gene following both PCRs indicates 
a reduction of the transmembrane channels and hence a 
deletion of the porin, OprD potentially indicating that 
resistance to the cabapenems may be attributed to this. 
To determine the expression of the Mex efflux 
pumps, RNA was extracted using the Roche High Pure 
RNA Isolation kit (Roche Diagnostics, Indianapolis, 
USA) followed by cDNA synthesis using the Roche 
Transcriptor First Strand cDNA Synthesis kit (Roche 
Diagnostics, Indianapolis, USA). Conventional PCR 
was performed on the G-Storm thermal cycler using the 
Qiagen Multiplex PCR kit and previously published 
primers [22].  
Amplified products were separated on a 2% agarose 
gel.  
 
Statistical Analysis 
Data were captured in a Microsoft Access database 
and exported to Microsoft Excel which was used for 
data analysis. Demographic data of patients from whom 
isolates were obtained were summarised and 
descriptive statistics were analysed using GraphPad 
Prism (version 5.01 for Windows, GraphPad Software, 
La Jolla California USA).  
 
Ethics 
Permission to conduct this study was obtained from 
the Human Research Ethics Committee (Medical) 
Figure 1. Monthly distribution of viable P. aeruginosa isolates 
collected over the two- year period, 2014 and 2015 (n = 669). 
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R14/49, University of Witwatersrand, Johannesburg, 
South Africa, Clearance certificate M10464. 
 
Results 
A total of 956 P. aeruginosa isolates were identified 
for the period of January 2014 to December 2015. Of 
these 686 were received in the laboratory, 17 of which 
were non-viable and one was missing/broken. The 
remaining 270 isolates were audit cases. This report 
analysed a total of 669 isolates that were received. 
Figure 1 demonstrates the monthly distribution of 
viable isolates collected over the two-year period. 
Majority of the isolates were submitted by Gauteng (n 
= 347, 52%), followed by the Western Cape (n = 237, 
35%), KwaZulu-Natal (n = 57, 9%) and the Free State 
(n = 28, 4%). Demographic data was limited. Males 
accounted for 52% (n = 349) and females accounted for 
45% (n = 306) with unknown sex information for the 
remaining 14 patients. Patient age ranged from < 1 year 
to 88 years with a median age of 36.9 years (n = 649). 
Age was unknown in 20 patients. Majority of the 
patients were from adult wards (71%, n = 72) followed 
by 25% (n = 170) from paediatric wards. Polymicrobial 
bloodstream infection was noted in 87 (13%) of the 
patients with various combinations of Gram-positive 
and Gram-negative organisms.  
Overall the susceptibility rate was high for all 
antibiotics tested (Table 1). A breakdown of the 
susceptibility by antibacterial agent and year is 
presented in Figure 2; overall the susceptibility rates 
decreased over the two-year period but were not 
significant (p = 0.8148). Susceptibility to the 
aminoglycosides ranged from 69% to 82% in 2014 and 
66% to 75% in 2015. The susceptibility to all three 
aminoglycoside antibiotics decreased from 2014 to 
2015. This was also observed for ciprofloxacin which 
was 74% in 2014 and decreased to 68% in 2015. There 
was a decrease in susceptibility of 2% for piperacillin 
and piperacillin/tazobactam from 2014 to 2015. 
Decreases in susceptibility were also seen for the third 
and fourth generation cephalosporins from 2014 to 
2015 (approximately 4% for ceftazidime and an 
inconsequential change of 0.16% for cefepime). 
Table 1. Antibiotic MIC50 and MIC90 breakpoints for P. aeruginosa isolates (n=669). 
 Susceptible 
isolates (n) 
Susceptibility 
(%) 
2014 2015 
MIC interpretive 
breakpoints (µg/mL)* 
   MIC50 MIC90 MIC50 MIC90 Susceptible Resistant 
Antibacterial agent*         
Aminoglycosides         
    Amikacin 522 78 ≤ 8 > 32 ≤ 8 > 32 ≤ 16 ≥ 64 
    Gentamicin 485 67 4 > 8 4 >  8 ≤ 4 ≥ 16 
    Tobramycin 477 71 ≤ 2 >  8 ≤ 2 >  8 ≤ 4 ≥ 16 
Fluoroquinolones         
    Ciprofloxacin 471 70 ≤ 0.5 >  2 ≤ 0.5 >  2 ≤ 1 ≥ 4 
    **Levofloxacin 467 70 ≤ 1 >  4 ≤ 1 >  4 ≤ 2 ≥ 8 
Extended Spectrum-Beta-Lactams        
    Piperacillin 488 73 ≤ 8 >  64 ≤ 8 >  64 ≤ 16 ≥ 128 
    Piperacillin/Tazobactam 495 74 ≤ 8 >  64 ≤ 8 >  64 ≤ 16/4 ≥ 128/4 
    Ceftazidime 513 77 2 >  16 2 >  16 ≤ 4 ≥ 16 
    Cefepime 494 74 4 > 16 4 > 16 ≤ 2 ≥ 16 
Carbapenems         
    Imipenem 459 69 ≤ 1 > 8 ≤ 1 > 8 ≤ 2 ≥ 8 
    Meropenem 458 69 ≤ 1 > 8 ≤ 1 > 8 ≤ 2 ≥ 8 
    Doripenem 514 77 ≤ 1 > 4 ≤ 1 > 4 ≤ 2 ≥ 8 
Aztreonam 491 74 4 16 4 > 16 ≤ 8 ≥ 32 
***Colistin 668 100 ≤ 2 ≤ 2 ≤ 2 ≤ 2 ≤ 2 ≥ 8 
Percentages have been rounded off; * Clinical Laboratory Standards Institute guidelines, 2016 [17]; For 2015, results for aztreonam were missing for 4 isolates 
(0.6%); **Note: Levofloxacin is generally not used as an anti-pseudomonal agent, particularly in treating bacteraemias; ***Note: One isolate could not be 
retrieved for colistin susceptibility testing on the Sensititre instrument. 
Figure 2. Percentage susceptibility to antibacterial agent, 2014 
and 2015. 
Percentages have been rounded off; For 2015, results for aztreonam were 
missing for 4 isolates (0.6%); One isolate could not be retrieved for 
colistin susceptibility testing on the Sensititre instrument. 
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  Table 2. Antimicrobial susceptibility overview for 669 P. aeruginosa isolates and genotype results for non-susceptible isolates. 
 Carbapenemase   Expression of efflux pumps 
Antibiotic 
Total no. of 
Isolates n, 
(%) 
OXA-48 and 
variants n, 
(%) 
NDM 
n, (%) 
VIM 
n, (%) 
IMP 
n, (%) 
GES 
n, (%) 
KPC 
n, (%) 
VEB-1 
n, (%) 
OprD 
deletion n, 
(%) 
MexAB-
OprM n, 
(%) 
MexCD-
OprJ n, 
(%) 
MexXY-
OprM (n), 
% 
MexEF-
OprN (n), 
% 
Imipenem              
Susceptible 459 (69) NT NT NT NT NT NT NT NT NT NT NT NT 
Nonsusceptib
le 
210 (31) 3 (0.45) 4 (0.6) 81 (12) 0 6 (0.9) 0 0 0 NT NT NT NT 
Meropenem              
Susceptible 458 (69) NT NT NT NT NT NT NT NT NT NT NT NT 
Nonsusceptib
le 
211 (32) 3 (0.45) 4 (0.6) 
78 
(11.7) 
0 6 (0.9) 0 0 1 (0.15) NT NT NT NT 
Doripenem              
Susceptible 514 (77) NT NT NT NT NT NT NT NT NT NT NT NT 
Nonsusceptib
le 
155 (23) 3 (0.45) 3 (0.45) 76 (11) 0 
5 
(0.75) 
0 0 0 NT NT NT NT 
Piperacillin              
Susceptible 488 (73) NT NT NT NT NT NT NT NT NT NT NT NT 
Nonsusceptib
le 
181 (27) NT NT NT NT NT NT 0 NT 137 (23) 137 (23) 132 (22) 136 (23) 
Ceftazidime              
Susceptible 513 (77) NT NT NT NT NT NT 0 NT NT NT NT NT 
Nonsusceptib
le 
156 (23) NT NT NT NT NT NT 0 NT 126 (21) 126 (21) 122 (20) 125 (21) 
Cefepime              
Susceptible 494 (74) NT NT NT NT NT NT 0 NT NT NT NT NT 
Nonsusceptib
le 
175 (26) NT NT NT NT NT NT 0 NT 133 (22) 133 (22) 130 (22) 131 (22) 
Aztreonam              
Susceptible 490 (74) NT NT NT NT NT NT 0 NT NT NT NT NT 
Nonsusceptib
le 
174 (26) NT NT NT NT NT NT 0 NT NT NT NT NT 
Ciprofloxaci
n 
             
Susceptible 468 (70) NT NT NT NT NT NT NT NT NT NT NT NT 
Nonsusceptib
le 
199 (30) NT NT NT NT NT NT NT NT 150 (25) 150 (25) 146 (24) 146 (24) 
Levofloxacin              
Susceptible 467 (70) NT NT NT NT NT NT NT NT NT NT NT NT 
Nonsusceptib
le 
202 (30) NT NT NT NT NT NT NT NT 150 (25) 150 (25) 146 (24) 146 (24) 
Amikacin              
Susceptible 522 (78) NT NT NT NT NT NT NT NT NT NT NT NT 
Nonsusceptib
le 
147 (22) NT NT NT NT NT NT NT NT 110 (18) NT 105 (18) NT 
Gentamicin              
Susceptible 449 (67) NT NT NT NT NT NT NT NT NT NT NT NT 
Nonsusceptib
le 
220 (33) NT NT NT NT NT NT NT NT 165 (28) NT 141 (24) NT 
Tobramycin              
Susceptible 479 (72) NT NT NT NT NT NT NT NT NT NT NT NT 
Nonsusceptib
le 
190 (28) NT NT NT NT NT NT NT NT 139 (23) NT 133 (22) NT 
Only isolates that produced a non-susceptible phenotypic (AST) result was selected for genotypic testing. Percentages have been rounded off; NT: not tested, 
denotes that the phenotypic (AST) result did not warrant the genotypic assay or a susceptible result was obtained; For the porin OprD, a deletion denotes a 
negative result i.e. OprD was not detected; OXA: oxacillinase, NDM: New Delhi Metallo-beta-lactamase, VIM: Verona Intergron-encoded Metallo-beta-
lactamase, IMP: Imipenem Metallo-beta-lactamase, GES: Guiana Extended-spectrum beta-lactamase, KPC: Klebsiella pneumoniae carbapenemase, VEB: 
Vietnam Extended-spectrum beta-lactamase, Opr: Outer membrane porin protein, Mex: multidrug efflux. 
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Decreases in susceptibility were observed for the 
carbapenems (approximately 5% for imipenem and 6% 
for meropenem and doripenem). There was 
approximately a 6% susceptibility decrease for 
aztreonam. All isolates were fully susceptible to 
colistin; however, one isolate could not be retrieved and 
was not tested on Sensititre for colistin susceptibility. 
There was no change in the MIC50 and MIC90 values for 
all antibiotics from 2014 to 2015 and the MIC50 was 
within the susceptible breakpoint range for most 
antibiotics with the exception of cefepime. The MIC90 
was within the susceptible breakpoint range for colistin 
only. With the exception of ceftazidime, cefepime, 
imipenem and meropenem, which were within the 
resistance breakpoint range, these MIC90 breakpoint 
values corresponded to the intermediate resistance 
category for the remaining antibiotics (Table 1).  
Table 2 demonstrates the overall numbers and 
percentages of the non-susceptible isolates per 
resistance genotype. Percentages were calculated from 
the total number of isolates (n = 669). The exceptions 
were as follows: for aztreonam results for five isolates 
were not included and percentages were calculated out 
of a total of 664; for the efflux pump PCRs, a total of 
70 samples were excluded from the analysis (sufficient 
RNA could not be extracted for 65 samples although the 
RNA extraction procedure was repeated, the isolates for 
two samples could not be retrieved and a further three 
samples were not processed) and percentages were 
calculated as the percentage of the total number of 
isolates tested (n = 599). 
Among resistant isolates, the highest proportion of 
resistance was attributable to the expression of efflux 
pumps (18-25%) and the lowest to porin deletion 
(0.15%). Carbapenemases (blaNDM, blaOXA-48 and 
variants, blaVIM and blaGES) accounted for 14%. BlaIMP, 
blaKPC and blaVEB-1 were not detected in any of the 
isolates (Table 2). 
Of the 669 isolates, 234 (35%) were phenotypically 
carbapenem non-susceptible and 94 (14%) produced a 
carbapenemase: blaNDM (n = 4, 0.6%); blaOXA-48 and 
variants (n = 3, 0.45%); blaVIM (n = 81, 12%) and blaGES 
(n = 6, 0.9%) (Table2). A combination of two genes was 
expressed in three isolates (blaNDM and blaOXA-48 and 
variants, n = 1; blaNDM and blaVIM, n = 1; blaVIM and 
blaGES, n = 1).  
For outer membrane impermeability, only one 
isolate displaying reduced susceptibility to meropenem 
had a porin deletion. This isolate did not possess any of 
the other carbapenem resistance mechanisms tested. 
Interestingly, OprD mutation did not confer imipenem 
resistance in any of the isolates, indicating that this is 
an uncommon resistance mechanism to carbapenems 
among our invasive P. aeruginosa isolates (Table 2).  
MexAB-OprM and MexCD-OprJ expression were 
detected in, 223 and 202 isolates, respectively. For 
MexXY-OprM, a total of 202 isolates were screened, 
197expressed the efflux pump and five did not, 
however these five isolates expressed the three other 
efflux pumps. For MexEF-OprN, a total of 223 isolates 
were screened, 219 expressed the efflux pump and four 
did not; however, these four isolates expressed the 
remaining three efflux pumps. 
The antimicrobial susceptibility profiles of isolates 
were compared to their genotypic results to establish 
how phenotypic resistance correlated with genotypic 
data (Table 2). For isolates with acquired resistance 
mechanisms, those positive for blaVIM showed the best 
correlation i.e. 81 of the 210 imipenem non-susceptible 
isolates, 78 of the 211 meropenem non-susceptible 
isolates and 76 of the 155 doripenem non-susceptible 
isolates harboured the blaVIM gene. For isolates having 
intrinsic resistance mechanisms, there was a good 
correlation between phenotype and genotype for efflux 
pump resistance mechanisms; for example, of 181 
piperacillin non-susceptible isolates, 137 expressed 
MexAB-OprM and MexCD-OprJ; 132 expressed 
MexXY-OprM and 136 expressed MexEF-OprN 
(Table 2). It should be noted that expression levels and 
not over-expression were investigated.  
When considering all mechanisms of resistance 
tested in non-susceptible isolates collectively, 
antimicrobial resistance could be solely attributed to a 
single mechanism of resistance for the following: 0.7% 
(4/599) to the presence of a carbapenemase (blaOXA-48 
and variants, 1/599; blaVIM, 3/599) and 25% (148/599) 
to the expression of efflux pumps. A combination of 
carbapenemase and efflux pumps resistance 
mechanisms accounted for resistance in 12% (71/599) 
of the isolates and a combination of porin deletion and 
efflux pumps in 0.17% (1/599) of the isolates tested.  
Table 3. Distribution of resistance genes/mechanisms per province. 
Province 
OXA-48 and 
variants (n) 
NDM 
(n) 
VIM 
(n) 
GES 
(n) 
OprD 
deletion (n) 
MexAB-
OprM (n) 
MexCD-
OprJ  (n) 
MexXY-
OprM (n) 
MexEF-
OprN (n) 
Gauteng - - 48 4 - 106 96 94 104 
Free state - 1 9 - 1 13 12 12 13 
KwaZulu- Natal 2 1 3 1 - 16 14 14 16 
Western Cape 1 2 21 1 - 88 80 77 86 
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The expression of efflux pumps was the 
predominant mechanism in all provinces (Table 3). 
 
Discussion 
Overall, majority of the isolates were from Gauteng 
(52%). This province constituted the largest number of 
sentinel sites which are also large academic centers. 
Delays in the receipt of appropriate antibiotics in 
patients with pseudomonas bacteraemia has been 
shown to be a risk factor for mortality and therefore it 
is important to have knowledge of the antimicrobial 
susceptibility profile of this pathogen [23]. The MIC50 
and MIC90 have not changed from 2014 to 2015 and the 
MIC50 was within the susceptible breakpoint range for 
most antibiotics. With the exception of colistin, the 
MIC90 of the remaining antibacterial agents was within 
the intermediate or resistance breakpoint range. It 
should be noted that the methodology used to report 
antimicrobial susceptibilities may have a limitation as 
the Microscan Walkaway system gives MIC 
breakpoints and not actual MIC values for certain 
antibiotics. The overall susceptibilities for all 
antibiotics were relatively high for antibacterial agents 
tested (ranging from 66% to 100%). High susceptibility 
rates were also seen in systemic antibiotics in a previous 
South African study which investigated P. aeruginosa 
strains isolated from wound infections from paediatric 
burn patients in a 36-month study period. Apart from 
piperacillin/tazobactam (63.9%), cefepime (82.0%), 
ciprofloxacin and ceftazidine (80.3% each), the other 
antimicrobial agents (tobramycin, gentamicin, 
amikacin, imipenem and meropenem) had more than 
90% sensitivity [24].This was also seen in a number of 
other studies in other countries investigating P. 
aeruginosa isolated from burn patients admitted into 
burn units over 1-year to 5-year study periods [25-29]. 
A Lithuanian study in bacteraemic patients showed 
similar findings to ours with low and relatively low 
resistance (ranging from 8.5% for amikacin to 39.4% 
for gentamicin) observed to the antibiotics tested. Other 
antibiotics tested included ciprofloxacin, piperacillin, 
ceftazidime, imipenem and meropenem. It should be 
noted that the sample size was small (n = 80) [30]. 
Another study in India [31] investigating 126 P. 
aeruginosa strains isolated from various sources 
showed varying degrees of resistance to different 
antimicrobials with no isolate being resistant to 
imipenem and meropenem, possibly due to the fact that 
these antibiotics are not administered in the hospital. 
Resistance was seen in a relatively small proportion of 
isolates (ranging from 18.3% for amikacin to 36.5% for 
cefoperazone) and other antimicrobial agents such as 
ciprofloxacin (31.7%). High resistance rates were seen 
for piperacillin (53.9%) [31]. This demonstrates that 
resistance patterns can vary depending on the use of 
antibiotics in the healthcare setting as this latter study 
has shown that P. aeruginosa is becoming resistant to 
antibiotics that are commonly used in the hospital.  
In our study the overall proportion of resistance to 
antibacterial agents was relatively low for all isolates 
(susceptible and non-susceptible) and similarly 
resistance mechanisms were detected in a small 
proportion of isolates tested: carbapenemases (96/669, 
14%), porin deletion (1/669, 1.5%) and efflux pumps 
(148/599, 25%). Thus efflux pumps were the 
predominant mechanism of resistance in our study. 
While transmission of antimicrobial resistance on 
plasmids (and other mobile genetic elements) is a 
concern, P. aeruginosa has the ability to develop 
resistance while the patient is on antimicrobial 
treatment resulting in mutational changes in the 
chromosome [32], a possible explanation for our 
finding which was also shown in a previous study 
where an increase of efflux-mediated resistance was 
observed during antibiotic treatment in patients 
diagnosed with hospital-acquired pneumonia [33]. 
Interestingly, although blaIMP, blaKPC and blaVEB-1 were 
not detected in any of the isolates in our study, they 
have been reported in P. aeruginosa in various studies 
[34-39].  
When only non-susceptible isolates were 
considered, a total of 94 (40%) of the 234 carbapenem 
non-susceptible isolates expressed carbapenemases, 
three of which expressed a combination of two genes; 
one (0.4%) of the 234 carbapenem non-susceptible 
isolates displayed a reduction of the outer-membrane 
channel porin, OprD. Isolates non-susceptible to one or 
more of the following antibiotics: ciprofloxacin, 
levofloxacin, amikacin, gentamicin, cefepime, 
ceftazidime and piperacillin expressed a minimum of 
two of the efflux pumps tested which is not surprising 
as these are intrinsic mechanisms of resistance.  
Varied resistance mechanisms may be evident 
because of the organism’s highly adaptable nature. It is 
able to alter its properties in response to environmental 
changes and can grow on a wide variety of substrates. 
It has a large genome (6.26Mbp) and encodes 5567 
genes. This considerably large genetic capacity may 
influence its ability to develop resistance particularly 
with excessive antibiotic usage [6]. This was evident by 
the combination of resistance mechanisms observed 
(carbapenemases and efflux pumps (12%) and porin 
deletion and efflux pumps (0.17%)). The phenotypic 
predictions were not entirely accurate in the 
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carbapenem non-susceptible group where 59% of the 
isolates did not harbour a carbapenemase. Furthermore, 
only one isolate in the carbapenem non-susceptible 
group displayed a porin deletion indicating that the 
phenotypic data does not reliably support the genotypic 
data. However, reduced expression of OprD was not 
investigated and carbapenem non-susceptibility may be 
due to carbapenemase variants and other 
carbapenemase types that were not screened for. 
Genotypic efflux pump results correlated in most part 
with phenotypic resistance and in this instance, the 
phenotypic data does to an extent support the genotypic 
data. This is not surprising as some of these are 
expressed constitutively at low levels. Correlation 
therefore differs for the mechanism of resistance 
investigated and the phenotypic data are not predictive 
of the resistance mechanism i.e. the antimicrobial 
resistance pattern is not specific for any resistance 
mechanism.  
A potential limitation is that we investigated efflux 
pump expression only and did not quantify levels of 
expression to determine upregulation of efflux pumps. 
However, no correlation between the level of 
transcription and resistance in P. aeruginosa clinical 
isolates was observed in some studies and therefore the 
measurement of expression level is not always essential 
for routine diagnosis [22,40,41]. Other limitations 
include the following: not all possible mechanisms of 
resistance for all antibiotics were investigated; due to 
the lack of patient demographic and clinical 
information, it was not possible to establish accurate 
trends in race, ward type and clinical outcome and we 
were not able to differentiate between community-
associated and healthcare-associated infection; and 
information on source of infection was not available.  
 
Conclusion 
This two-year surveillance study describes the 
antimicrobial susceptibility profiles and resistance 
mechanisms in P. aeruginosa isolates from patients 
with bacteraemia. Furthermore, this study demonstrated 
the presence of multiple resistance genes/mechanisms 
in four provinces in conjunction with the antimicrobial 
susceptibility profiles of the P. aeruginosa isolates. We 
established baseline data on the distribution of different 
mechanisms of resistance in P. aeruginosa. These data 
can be used as a reference for antibiotic resistance 
patterns and resistance mechanisms in invasive P. 
aeruginosa isolates from public South African 
hospitals. The information will be useful in guiding 
policy for antimicrobial stewardship committees and 
hospital formularies, and for the development of 
national treatment guidelines.  
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